Salix Pharmaceuticals to Unveil Amiselimod Phase 2 Results at Digestive Disease Week 2024

Salix Pharmaceuticals, part of Bausch Health Companies Inc., has announced plans to present pivotal data from a Phase 2 clinical trial at Digestive Disease Week 2024. The trial evaluates the efficacy and safety of Amiselimod in treating active ulcerative colitis. These findings will be showcased in Washington, D.C., during the IMIBD Late Breakers and Innovations in IBD session on May 19, 2024.

The study, titled "Amiselimod for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled trial" (Abstract #4094796), was a 12-week, double-blind, placebo-controlled and randomized dose trial. It involved 320 patients who have mildly to moderately active ulcerative colitis. Dr. Tage Ramakrishna, the Chief Medical Officer at Bausch Health, highlighted the dedication of the company to pioneering new therapies in gastrointestinal diseases with this innovative treatment approach.